Results 71 to 80 of about 13,816 (168)

Amphotericin-B-liposomal

Reactions Weekly, 2022
  +5 more sources

Visceral Leishmaniasis (VL) Clinical Presentation, Laboratory Findings, Treatment Options and Outcome

Iranian Journal of Parasitology
Background: Black disease, also known as visceral leishmaniasis (VL), is a parasitic illness caused by various Leishmania species. The risk of morbidity and mortality increases with delayed diagnosis and treatment.
Mahmoud Khodabandeh, Elham Moradian, Maedeh Sarvari, Mahsa Soti Khiabani   +3 more
doaj  

Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B

The Turkish Journal of Pediatrics, 2002
Visceral leishmaniasis is a worldwide, disseminated intracellular protozoal infection that usually manifests by fever, hepatosplenomegaly, anemia, thrombocytopenia, leukopenia and hypergammaglobulinemia. Although anemia is a usual finding, Coombs'
Embiya Dilber, Erol Erduran, Yasemin Işik   +2 more
doaj  

Liposomal amphotericin B in the treatment of pediatric gastrointestinal basidiobolomycosis. [PDF]

J Med Case Rep
Forooghi M, Hamzavi SS, Yousufzai S, Geramizadeh B, Sharifi S, Nasiri S.   +5 more
europepmc   +1 more source

Nebulized Liposomal Amphotericin B as an Alternative Therapy for an <i>Aspergillus</i> Tracheal Plaque. [PDF]

Case Rep Infect Dis
Valdes-Camacho S, Gutierrez-Gallegos P, Barrios-Ruiz A, Vaca-Cartagena BF, Yu Lee-Mateus A, Fernandez-Bussy I, Walsh KL, Robertson KS, Fernandez-Bussy S, Abia-Trujillo D.   +9 more
europepmc   +1 more source

Can liposomal amphotericin B be used as a preventive measure for cryptococcal meningitis? [PDF]

Expert Rev Anti Infect Ther
Schwartz EL, Bahr NC, Rajasingham R.
europepmc   +1 more source

Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations. [PDF]

J Antimicrob Chemother
Maertens J, Birne R, Felton T, Neofytos D, Hoenigl M.   +4 more
europepmc   +1 more source

Real-World Efficacy and Safety of Liposomal Amphotericin B for Invasive Fungal Disease in Patients with Hematologic Malignancies: A Multicenter Retrospective Study. [PDF]

Drug Des Devel Ther
Lu T, Zhang J, Liu D, Gu B, Yang X, Lyu F, Zhang J, Hu X, Xiong M, Ma X, Wang J.   +10 more
europepmc   +1 more source

A step toward defining optimal liposomal amphotericin B treatment duration in pulmonary mucormycosis: results from emulated trials. [PDF]

Antimicrob Agents Chemother
Coste A, Paccoud O, Danion F, Conrad A, Poirée S, Le Bourgeois A, Defrance C, Letscher-Bru V, Morio F, Gastinne T, Bougnoux M-E, Suarez F, Le Gal S, Dupont D, Ader F, Halfon-Domenech C, Ducastelle-Leprêtre S, Botterel F, Millon L, Guillerm G, Ansart S, Boutoille D, Ledoux M-P, Herbrecht J-E, Robin C, Melica G, Garcia-Hermoso D, Lortholary O, Herbrecht R, Porcher R, Lanternier F.   +30 more
europepmc   +1 more source

Successful desensitization to liposomal amphotericin B for the treatment of disseminated cryptococcosis in pregnancy: a case report. [PDF]

ASM Case Rep
Ajao SO, Nelson JM, Yassin A, Rosenfeld EB, Brandt JS, Monteleone C, Bhatt PJ, Abdul Azim A.   +7 more
europepmc   +1 more source